Biovica

Biovica is a Swedish biotechnology company founded in 2009, dedicated to developing and commercializing blood-based biomarker assays to improve the monitoring of modern cancer therapies and better predict patient outcomes. Biovica is supported by the European Commission and has been selected to receive funding under the second phase of the Horizon 2020 program.